MedTrace Logo

Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT00707980 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 836

Last updated 2013-12-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the long-term efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.

Conditions

Interventions

DRUG

Vortioxetine

Encapsulated vortioxetine immediate-release tablets

Sponsors & Collaborators

  • H. Lundbeck A/S

    collaborator INDUSTRY

  • Takeda

    lead INDUSTRY

Principal Investigators

  • Medical Director, Clinical Science · Takeda

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
76 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2010-07-31
Completion
2010-08-31

Countries

  • United States
  • Australia
  • Croatia
  • France
  • Germany
  • Latvia
  • Lithuania
  • Malaysia
  • Netherlands
  • Poland
  • Russia
  • Serbia
  • South Africa
  • South Korea
  • Taiwan
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00707980 on ClinicalTrials.gov